Trial Search Results
Pilot Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
A research study on the diagnosis of spread of disease for children who have been diagnosed with solid tumors using a new whole body imaging technique and a new MR contrast agent (ferumoxytol). Standard tests that are used to determine the extent and possible spread of a child's disease include magnetic resonance (MR) imaging, computed tomography (CT), Positron Emission Tomography (PET) as well as bone scanning, and metaiodobenzylguanidine (MIBG) scanning. The purpose of this study is to determine if newer imaging tests referred to as whole body diffusion-weighted MR and whole body PET/MR can detect the extent and spread of the disease as accurately or even better as the standard tests (CT, MR and/or PET/CT). The advantage of the new imaging test is that it is associated with no or significantly reduced radiation exposure compared to standard CT and PET/CT imaging tests. The results of whole body MR and PET/MR will be compared with that of the conventional, standard imaging studies for tumor detecting.
Stanford is currently accepting patients for this trial.
Heike E Daldrup-Link
- Procedure: WB-DW-MR scan
- Procedure: 18F-FDG PET scan
- Drug: Ferumoxytol
- age of less than 40 years
- diagnosis of a malignant lymphoma or sarcoma
- scheduled for or completed a PET or PET/CT tumor staging procedure.
- MR-incompatible metal implants
- need of sedation
Ages Eligible for Study
N/A - 40 Years
Genders Eligible for Study